These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 16400839

  • 1. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS.
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [Abstract] [Full Text] [Related]

  • 2. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [Abstract] [Full Text] [Related]

  • 3. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M, Miravalle A, Vollmer T.
    J Neuroimmunol; 2011 Jun 01; 235(1-2):9-17. PubMed ID: 21402415
    [Abstract] [Full Text] [Related]

  • 4. Lessons from randomised direct comparative trials.
    Achiron A, Fredrikson S.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [Abstract] [Full Text] [Related]

  • 5. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 2008 Nov 01; 164(11):917-26. PubMed ID: 18790510
    [Abstract] [Full Text] [Related]

  • 6. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W, Ziemssen T.
    Autoimmun Rev; 2007 Aug 01; 6(7):469-75. PubMed ID: 17643935
    [Abstract] [Full Text] [Related]

  • 7. New options for early treatment of multiple sclerosis.
    Tintoré M.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [Abstract] [Full Text] [Related]

  • 8. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA, Kim E, Moodie J.
    Int J Nanomedicine; 2006 Feb 01; 1(3):283-9. PubMed ID: 17717969
    [Abstract] [Full Text] [Related]

  • 9. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T, Schrempf W.
    Int Rev Neurobiol; 2007 Feb 01; 79():537-70. PubMed ID: 17531858
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glatiramer acetate.
    Comi G, Moiola L.
    Neurologia; 2002 May 09; 17(5):244-58. PubMed ID: 12031214
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH.
    Curr Med Res Opin; 2007 Jun 09; 23(6):1199-208. PubMed ID: 17559719
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Glatiramer acetate (Copaxone).
    Francis DA.
    Int J Clin Pract; 2001 Jun 09; 55(6):394-8. PubMed ID: 11501229
    [Abstract] [Full Text] [Related]

  • 20. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
    Kohriyama T, Higaki M, Matsumoto M.
    Nihon Rinsho; 2003 Aug 09; 61(8):1381-7. PubMed ID: 12962027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.